Azithromcyin

ApprovedSmall molecule

BBin Cao

Azithromcyin is one of 39 small molecule programs targeting Peri-Implantitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peri-ImplantitisActive, not recruiting

Cystic FibrosisActive, not recruiting

Peri-ImplantitisApproved

Active, not recruiting

Cystic FibrosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

Azithromcyin

BBin Cao

Approved

1 2

Onglyza

AstraZeneca

Preclinical

2 3

Calciferol

Alnylam Pharmaceuticals

Preclinical

1 4

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

3 5

Actimmune

HHorizon Therapeutics Ireland DAC

Preclinical

2 6

Proair HFA

GGlaxo Dba Glaxosmithkline

Preclinical

2 7

Aztreonam Lysine

Gilead

Preclinical

5 8

Advil

KKenvue Brands

Preclinical

1 9

Feosol

AAuerbach Hematology Oncology Associates P C

Preclinical

1 10

Capromorelin

UUniversity of Aarhus

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Post-ApprovalNot yet recruiting

Peri-Implantitis

NCT06715150

Q4 2027

Post-ApprovalRecruiting

Study completion

NCT07084402

Q3 2031

Phase 2Not yet recruiting

Cystic Fibrosis

NCT07485010

Clinical

Trials by Indication[1]

Peri-Implantitis1 trial

Non-Surgical Treatment of Peri-implantitis with Systemic Azithromycin or Placebo

Not yet recruiting·UUniversity of Santiago de Compostela·Phase 4·NCT06715150·52 enrolled

MPA1 trial

Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger

Completed·UUniversity of California, San Francisco·Phase 4·NCT00618449·1,139 enrolled

Cystic Fibrosis1 trial

Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

Not yet recruiting·TThe University of Queensland·Phase 2·NCT07485010·300 enrolled

Unspecified1 trial

Short-term Bactericidal Effect of Contezolid in MAC-PD

Recruiting·BBin Cao·Phase 4·NCT07084402·188 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Azithromcyin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Azithromcyin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Azithromcyin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bin Cao company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: BBin Cao

Azithromcyin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q3 2031

Trials by Indication[1]

Peri-Implantitis1 trial

MPA1 trial

Cystic Fibrosis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News